REGENXBIO (RGNX) Stock Forecast, Price Target & Predictions
RGNX Stock Forecast
REGENXBIO stock forecast is as follows: an average price target of $29.75 (represents a 290.42% upside from RGNX’s last price of $7.62) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
RGNX Price Target
The average price target for REGENXBIO (RGNX) is $29.75 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $40.00 to $18.00. This represents a potential 290.42% upside from RGNX's last price of $7.62.
RGNX Analyst Ratings
According to 6 Wall Street analysts, REGENXBIO's rating consensus is 'Buy'. The analyst rating breakdown for RGNX stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
REGENXBIO Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 15, 2024 | Judah Frommer | Morgan Stanley | $22.00 | $11.14 | 97.49% | 188.71% |
| Oct 10, 2024 | Danielle Brill | Raymond James | $18.00 | $9.19 | 95.97% | 136.22% |
| Sep 05, 2024 | Yi Chen | H.C. Wainwright | $39.00 | $11.38 | 242.86% | 411.81% |
| Jun 24, 2024 | Annabel Samimy | Stifel Nicolaus | $40.00 | $12.79 | 212.74% | 424.93% |
| Jun 07, 2024 | Paul Choi | Goldman Sachs | $38.00 | $13.76 | 176.16% | 398.69% |
| May 15, 2024 | Yi Chen | H.C. Wainwright | $38.00 | $15.80 | 140.51% | 398.69% |
| Mar 11, 2024 | Yi Chen | H.C. Wainwright | $36.00 | $22.85 | 57.55% | 372.44% |
| Mar 08, 2024 | Luca Issi | RBC Capital | $35.00 | $22.75 | 53.85% | 359.32% |
The latest REGENXBIO stock forecast, released on Nov 15, 2024 by Judah Frommer from Morgan Stanley, set a price target of $22.00, which represents a 97.49% increase from the stock price at the time of the forecast ($11.14), and a 188.71% increase from RGNX last price ($7.62).
REGENXBIO Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 8 |
| Avg Price Target | - | $20.00 | $33.25 |
| Last Closing Price | $7.62 | $7.62 | $7.62 |
| Upside/Downside | -100.00% | 162.47% | 336.35% |
In the current month, the average price target of REGENXBIO stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to REGENXBIO's last price of $7.62. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 18, 2024 | Raymond James | Outperform | Outperform | Hold |
| Oct 10, 2024 | Raymond James | Buy | Buy | Hold |
| Sep 04, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 05, 2024 | Goldman Sachs | Underperform | Underperform | Hold |
| Aug 05, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 20, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Jun 07, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 07, 2024 | Goldman Sachs | Buy | Initialise | |
| May 15, 2024 | Wedbush | Buy | Buy | Hold |
| May 15, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 12, 2024 | Wedbush | Buy | Buy | Hold |
| Mar 08, 2024 | RBC Capital | Outperform | Upgrade | |
| Mar 06, 2024 | Wedbush | Neutral | Neutral | Hold |
| Mar 06, 2024 | Raymond James | Underperform | Underperform | Hold |
| Mar 06, 2024 | Leerink Partners | Outperform | Upgrade | |
| Feb 12, 2024 | Wedbush | Neutral | Neutral | Hold |
| Mar 06, 2023 | Morgan Stanley | Overweight | Overweight | Hold |
REGENXBIO's last stock rating was published by Raymond James on Nov 18, 2024. The company gave RGNX a "Outperform" rating, the same as its previous rate.
REGENXBIO Financial Forecast
REGENXBIO Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $22.21M | $28.91M | $19.98M | $19.14M | $31.34M | $26.51M | $32.65M | $22.22M | - | $30.77M | $22.04M | $18.88M | $21.45M | $98.91M | $16.57M | $17.64M | $11.77M | $14.70M | $7.88M | $884.00K | $132.39M | $455.00K |
| Avg Forecast | $82.88M | $69.65M | $119.84M | $20.68M | $23.46M | $23.63M | $22.97M | $23.52M | $34.01M | $26.14M | $34.50M | $31.22M | $37.45M | $30.81M | $28.31M | $27.22M | $427.83M | $33.17M | $21.17M | $18.59M | $26.31M | $21.45M | $20.46M | $19.62M | $39.67M | $7.46M | $22.61M | $854.20K | $43.55M | $421.71K |
| High Forecast | $102.40M | $86.06M | $148.07M | $25.29M | $26.55M | $24.00M | $22.97M | $23.52M | $50.11M | $26.65M | $42.63M | $38.57M | $46.27M | $30.81M | $28.31M | $27.22M | $427.83M | $33.17M | $21.17M | $18.59M | $26.31M | $21.45M | $20.46M | $19.62M | $39.67M | $7.46M | $22.61M | $1.03M | $52.26M | $506.05K |
| Low Forecast | $58.93M | $49.53M | $85.21M | $16.07M | $15.69M | $23.26M | $22.97M | $23.52M | $24.82M | $25.63M | $24.53M | $22.19M | $26.63M | $30.81M | $28.31M | $27.22M | $427.83M | $33.17M | $21.17M | $18.59M | $26.31M | $21.45M | $20.46M | $19.62M | $39.67M | $7.46M | $22.61M | $683.36K | $34.84M | $337.36K |
| # Analysts | 1 | 1 | 1 | 4 | 7 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 10 | 7 | 20 |
| Surprise % | - | - | - | - | - | - | - | - | 0.65% | 1.11% | 0.58% | 0.61% | 0.84% | 0.86% | 1.15% | 0.82% | - | 0.93% | 1.04% | 1.02% | 0.82% | 4.61% | 0.81% | 0.90% | 0.30% | 1.97% | 0.35% | 1.03% | 3.04% | 1.08% |
REGENXBIO's average Quarter revenue forecast for Mar 24 based on 3 analysts is $23.52M, with a low forecast of $23.52M, and a high forecast of $23.52M. RGNX's average Quarter revenue forecast represents a 5.91% increase compared to the company's last Quarter revenue of $22.21M (Dec 23).
REGENXBIO EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 7 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 10 | 7 | 20 |
| EBITDA | - | - | - | - | - | - | - | - | $-63.90M | $-64.90M | $-73.11M | $-66.09M | $-57.69M | $-67.48M | $-59.74M | $-68.84M | $313.60M | $-48.87M | $-49.07M | $-41.50M | $-37.62M | $10.96M | $-32.13M | $-38.04M | $-26.93M | $-32.88M | $163.00K | $-30.68M | $105.07M | $-21.44M |
| Avg Forecast | $-54.13M | $-45.50M | $-78.28M | $-13.51M | $-15.33M | $-15.44M | $-15.01M | $-38.30M | $-22.22M | $-17.07M | $-22.54M | $-40.97M | $-10.07M | $-20.97M | $-19.27M | $-43.82M | $-291.11M | $-22.57M | $-14.41M | $-44.10M | $-17.90M | $-14.59M | $-13.92M | $-28.86M | $-26.99M | $-5.07M | $-15.39M | $-29.61M | $-29.63M | $-19.75M |
| High Forecast | $-38.49M | $-32.35M | $-55.66M | $-10.50M | $-10.25M | $-15.20M | $-15.01M | $-30.64M | $-16.21M | $-16.74M | $-16.03M | $-32.77M | $-8.06M | $-20.97M | $-19.27M | $-35.05M | $-291.11M | $-22.57M | $-14.41M | $-35.28M | $-17.90M | $-14.59M | $-13.92M | $-23.09M | $-26.99M | $-5.07M | $-15.39M | $-23.69M | $-23.71M | $-15.80M |
| Low Forecast | $-66.89M | $-56.22M | $-96.72M | $-16.52M | $-17.34M | $-15.68M | $-15.01M | $-45.97M | $-32.73M | $-17.41M | $-27.85M | $-49.16M | $-12.09M | $-20.97M | $-19.27M | $-52.58M | $-291.11M | $-22.57M | $-14.41M | $-52.92M | $-17.90M | $-14.59M | $-13.92M | $-34.63M | $-26.99M | $-5.07M | $-15.39M | $-35.54M | $-35.56M | $-23.70M |
| Surprise % | - | - | - | - | - | - | - | - | 2.88% | 3.80% | 3.24% | 1.61% | 5.73% | 3.22% | 3.10% | 1.57% | -1.08% | 2.17% | 3.41% | 0.94% | 2.10% | -0.75% | 2.31% | 1.32% | 1.00% | 6.48% | -0.01% | 1.04% | -3.55% | 1.09% |
4 analysts predict RGNX's average Quarter EBITDA for Mar 22 to be $-43.82M, with a high of $-35.05M and a low of $-52.58M. This is -113.97% lower than REGENXBIO's previous annual EBITDA (Dec 21) of $313.60M.
REGENXBIO Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 7 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 10 | 7 | 20 |
| Net Income | - | - | - | - | - | - | - | - | $-62.89M | $-61.87M | $-72.06M | $-69.95M | $-59.94M | $-79.92M | $-73.83M | $-76.72M | $307.02M | $-58.41M | $-57.64M | $-50.14M | $-46.24M | $8.79M | $-33.76M | $-40.04M | $-26.46M | $-34.58M | $-1.46M | $-32.23M | $104.24M | $-21.99M |
| Avg Forecast | $-6.73M | $-13.82M | $39.83M | $-59.54M | $-57.15M | $-57.01M | $-65.61M | $-43.19M | $-64.53M | $-74.00M | $-60.28M | $-46.19M | $-9.90M | $-74.48M | $-71.09M | $-49.40M | $389.25M | $-52.26M | $-56.42M | $-53.27M | $-56.22M | $-50.46M | $-44.95M | $-30.37M | $-33.65M | $-36.13M | $-29.35M | $-31.10M | $108.41M | $-20.26M |
| High Forecast | $-4.20M | $-8.63M | $52.03M | $-52.65M | $-49.50M | $-35.60M | $-40.96M | $-34.55M | $-59.45M | $-46.20M | $-37.63M | $-36.95M | $-7.92M | $-74.48M | $-71.09M | $-39.52M | $389.25M | $-52.26M | $-56.42M | $-42.62M | $-56.22M | $-50.46M | $-44.95M | $-24.30M | $-33.65M | $-36.13M | $-29.35M | $-24.88M | $130.09M | $-16.21M |
| Low Forecast | $-8.79M | $-18.05M | $24.87M | $-66.43M | $-61.20M | $-74.48M | $-85.70M | $-51.83M | $-70.12M | $-96.66M | $-78.74M | $-55.43M | $-11.88M | $-74.48M | $-71.09M | $-59.29M | $389.25M | $-52.26M | $-56.42M | $-63.93M | $-56.22M | $-50.46M | $-44.95M | $-36.45M | $-33.65M | $-36.13M | $-29.35M | $-37.32M | $86.73M | $-24.31M |
| Surprise % | - | - | - | - | - | - | - | - | 0.97% | 0.84% | 1.20% | 1.51% | 6.06% | 1.07% | 1.04% | 1.55% | 0.79% | 1.12% | 1.02% | 0.94% | 0.82% | -0.17% | 0.75% | 1.32% | 0.79% | 0.96% | 0.05% | 1.04% | 0.96% | 1.09% |
REGENXBIO's average Quarter net income forecast for Mar 22 is $-49.40M, with a range of $-59.29M to $-39.52M. RGNX's average Quarter net income forecast represents a -116.09% decrease compared to the company's last Quarter net income of $307.02M (Dec 21).
REGENXBIO SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 7 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 10 | 7 | 20 |
| SG&A | - | - | - | - | - | - | - | - | $19.08M | $23.08M | $23.70M | $22.63M | $21.21M | $20.92M | $20.83M | $22.32M | $22.04M | $21.03M | $18.43M | $17.84M | $17.57M | $15.86M | $15.55M | $14.90M | $14.49M | $12.41M | $13.34M | $11.56M | $8.41M | $6.67M |
| Avg Forecast | $62.81M | $52.79M | $90.82M | $15.67M | $17.78M | $17.91M | $17.41M | $12.56M | $25.78M | $19.81M | $26.15M | $13.44M | $5.42M | $23.35M | $21.46M | $14.37M | $324.24M | $25.14M | $16.05M | $14.09M | $19.94M | $16.25M | $15.51M | $11.30M | $30.06M | $5.65M | $17.14M | $647.38K | $8.74M | $319.60K |
| High Forecast | $77.61M | $65.23M | $112.22M | $19.16M | $20.12M | $18.19M | $17.41M | $15.08M | $37.97M | $20.20M | $32.31M | $16.12M | $6.50M | $23.35M | $21.46M | $17.25M | $324.24M | $25.14M | $16.05M | $14.09M | $19.94M | $16.25M | $15.51M | $13.56M | $30.06M | $5.65M | $17.14M | $776.85K | $10.49M | $383.52K |
| Low Forecast | $44.66M | $37.53M | $64.58M | $12.18M | $11.89M | $17.63M | $17.41M | $10.05M | $18.81M | $19.42M | $18.59M | $10.75M | $4.34M | $23.35M | $21.46M | $11.50M | $324.24M | $25.14M | $16.05M | $14.09M | $19.94M | $16.25M | $15.51M | $9.04M | $30.06M | $5.65M | $17.14M | $517.90K | $7.00M | $255.68K |
| Surprise % | - | - | - | - | - | - | - | - | 0.74% | 1.17% | 0.91% | 1.68% | 3.91% | 0.90% | 0.97% | 1.55% | 0.07% | 0.84% | 1.15% | 1.27% | 0.88% | 0.98% | 1.00% | 1.32% | 0.48% | 2.20% | 0.78% | 17.85% | 0.96% | 20.86% |
REGENXBIO's average Quarter SG&A projection for Mar 24 is $12.56M, based on 3 Wall Street analysts, with a range of $10.05M to $15.08M. The forecast indicates a -34.15% fall compared to RGNX last annual SG&A of $19.08M (Dec 23).
REGENXBIO EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 7 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 10 | 7 | 20 |
| EPS | - | - | - | - | - | - | - | - | $-1.43 | $-1.41 | $-1.66 | $-1.61 | $-1.38 | $-1.85 | $-1.71 | $-1.79 | $7.18 | $-1.37 | $-1.36 | $-1.20 | $-1.24 | $0.24 | $-0.91 | $-1.08 | $-0.72 | $-0.94 | $-0.04 | $-0.89 | $3.30 | $-0.82 |
| Avg Forecast | $-0.13 | $-0.27 | $0.78 | $-1.17 | $-1.13 | $-1.12 | $-1.29 | $-1.26 | $-1.27 | $-1.46 | $-1.19 | $-1.42 | $-1.28 | $-1.47 | $-1.40 | $-1.54 | $7.69 | $-1.03 | $-1.12 | $-1.28 | $-1.11 | $-1.00 | $-0.89 | $-0.84 | $-0.67 | $-0.71 | $-0.58 | $-0.86 | $1.04 | $-0.70 |
| High Forecast | $-0.08 | $-0.17 | $1.02 | $-1.04 | $-0.97 | $-0.70 | $-0.81 | $-0.79 | $-1.17 | $-0.91 | $-0.74 | $-0.89 | $-0.80 | $-1.47 | $-1.40 | $-1.54 | $7.69 | $-1.03 | $-1.12 | $-1.28 | $-1.11 | $-1.00 | $-0.89 | $-0.84 | $-0.67 | $-0.71 | $-0.58 | $-0.86 | $1.25 | $-0.56 |
| Low Forecast | $-0.17 | $-0.36 | $0.49 | $-1.31 | $-1.20 | $-1.47 | $-1.69 | $-1.64 | $-1.38 | $-1.90 | $-1.55 | $-1.86 | $-1.68 | $-1.47 | $-1.40 | $-1.54 | $7.69 | $-1.03 | $-1.12 | $-1.28 | $-1.11 | $-1.00 | $-0.89 | $-0.84 | $-0.67 | $-0.71 | $-0.58 | $-0.86 | $0.83 | $-0.84 |
| Surprise % | - | - | - | - | - | - | - | - | 1.13% | 0.97% | 1.40% | 1.13% | 1.08% | 1.26% | 1.22% | 1.16% | 0.93% | 1.33% | 1.22% | 0.94% | 1.12% | -0.24% | 1.02% | 1.29% | 1.08% | 1.32% | 0.07% | 1.03% | 3.17% | 1.17% |
According to 4 Wall Street analysts, REGENXBIO's projected average Quarter EPS for Mar 22 is $-1.54, with a low estimate of $-1.54 and a high estimate of $-1.54. This represents a -121.44% decrease compared to RGNX previous annual EPS of $7.18 (Dec 21).
REGENXBIO Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PASG | Passage Bio | $0.67 | $6.00 | 795.52% | Buy |
| FDMT | 4D Molecular Therapeutics | $6.32 | $38.33 | 506.49% | Buy |
| ANTX | AN2 Therapeutics | $1.34 | $5.00 | 273.13% | Buy |
| RCKT | Rocket Pharmaceuticals | $11.92 | $42.00 | 252.35% | Buy |
| RGNX | REGENXBIO | $8.47 | $29.75 | 251.24% | Buy |
| QURE | uniQure | $16.46 | $53.67 | 226.06% | Buy |
| KZR | Kezar Life Sciences | $6.52 | $17.50 | 168.40% | Buy |
| PLRX | Pliant Therapeutics | $14.37 | $35.50 | 147.04% | Buy |
| IMCR | Immunocore | $29.40 | $70.20 | 138.78% | Buy |
| STOK | Stoke Therapeutics | $12.10 | $26.50 | 119.01% | Buy |
| DAWN | Day One Biopharmaceuticals | $12.64 | $24.00 | 89.87% | Buy |
| RNA | Avidity Biosciences | $32.74 | $59.00 | 80.21% | Buy |
| REPL | Replimune Group | $11.72 | $19.00 | 62.12% | Buy |
| RVMD | Revolution Medicines | $45.16 | $65.67 | 45.42% | Buy |
| PTGX | Protagonist Therapeutics | $40.69 | $57.33 | 40.89% | Buy |
| MIRM | Mirum Pharmaceuticals | $42.65 | $57.00 | 33.65% | Buy |
| CRNX | Crinetics Pharmaceuticals | $55.37 | $69.00 | 24.62% | Buy |